董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Roland Diggelmann | 男 | Chairman of the Board | 56 | 25.10万美元 | 0.05 | 2024-05-09 |
| Richard Francis | 男 | Director | 55 | 23.90万美元 | 0.34 | 2024-05-09 |
| Elisha W. Finney | 女 | Director | 62 | 25.50万美元 | 0.19 | 2024-05-09 |
| Domitille Doat Le Bigot | 女 | Director | 51 | 23.60万美元 | 0.08 | 2024-05-09 |
| Wolfgang Wienand | 男 | Independent Director | 52 | 16.34万美元 | 0.0049 | 2024-05-09 |
| Michael A. Kelly | 男 | Director | 67 | 25.10万美元 | 0.56 | 2024-05-09 |
| Thomas P. Salice | 男 | Director | 64 | 31.02万美元 | 8.04 | 2024-05-09 |
| Ingrid Zhang | 女 | Director | 51 | 23.45万美元 | 0.01 | 2024-05-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Patrick Kaltenbach | 男 | President and Chief Executive Officer | 60 | 841.73万美元 | 1.09 | 2024-05-09 |
| Shawn P. Vadala | 男 | Chief Financial Officer | 55 | 202.71万美元 | 2.13 | 2024-05-09 |
| Peter Aggersbjerg | 男 | Head of Divisions | 55 | 214.85万美元 | 未持股 | 2024-05-09 |
| Gerhard Keller | 男 | Head of Process Analytics | 56 | 107.12万美元 | 0.27 | 2024-05-09 |
| Richard Wong | 男 | Head of Asia/Pacific Market Organizations | 59 | 102.82万美元 | 0.24 | 2024-05-09 |
| Marc de la Gueronniere | 男 | Head of European and North American Market Organizations | 60 | 155.34万美元 | 1.32 | 2024-05-09 |
| Christian Magloth | 男 | Head of Human Resources | 58 | 未披露 | 未持股 | 2024-05-09 |
董事简历
中英对照 | 中文 | 英文- Roland Diggelmann
-
Roland Diggelmann，自2022年8月起担任董事。他在审计委员会和薪酬委员会任职。他最近于2019年至2022年担任Smith & Nephew Plc首席执行官。在此之前，他曾于2012年至2018年担任Roche Diagnostics首席执行官，并于2008年至2012年担任亚太区董事总经理。在其职业生涯早期，Diggelmann曾在Zimmer Holdings、Centerpulse和Sulzer Medica担任多个高级管理职位。他是Sonova Holding AG的董事和提名与薪酬委员会成员，并且是瑞士公民。
Roland Diggelmann,has been a director since August 2022. The board has nominated Mr. Diggelmann to serve as Board Chair beginning May 2024. He serves on the Audit and Compensation Committees and will step down from these committees in May 2024 given his planned role as Board Chair. He most recently served as the Chief Executive Officer of Smith & Nephew Plc from 2019-2022. Prior to this role, he was CEO of Roche Diagnostics from 2012 to 2018 and managing director of the Asia Pacific region from 2008 to 2012.Earlier in his career, Mr. Diggelmann served in various senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica. He is a Director and serves on the Nomination and Compensation Committee at Sonova Holding AG, and is a Swiss citizen. - Roland Diggelmann，自2022年8月起担任董事。他在审计委员会和薪酬委员会任职。他最近于2019年至2022年担任Smith & Nephew Plc首席执行官。在此之前，他曾于2012年至2018年担任Roche Diagnostics首席执行官，并于2008年至2012年担任亚太区董事总经理。在其职业生涯早期，Diggelmann曾在Zimmer Holdings、Centerpulse和Sulzer Medica担任多个高级管理职位。他是Sonova Holding AG的董事和提名与薪酬委员会成员，并且是瑞士公民。
- Roland Diggelmann,has been a director since August 2022. The board has nominated Mr. Diggelmann to serve as Board Chair beginning May 2024. He serves on the Audit and Compensation Committees and will step down from these committees in May 2024 given his planned role as Board Chair. He most recently served as the Chief Executive Officer of Smith & Nephew Plc from 2019-2022. Prior to this role, he was CEO of Roche Diagnostics from 2012 to 2018 and managing director of the Asia Pacific region from 2008 to 2012.Earlier in his career, Mr. Diggelmann served in various senior management roles at Zimmer Holdings, Centerpulse, and Sulzer Medica. He is a Director and serves on the Nomination and Compensation Committee at Sonova Holding AG, and is a Swiss citizen.
- Richard Francis
-
Richard Francis从2014年5月1日开始一直担任山德士公司（Sandoz）的部门领导。他是诺华制药（Novartis）执行委员会委员。Francis先生从百健艾迪（Biogen Idec）离职加入诺华制药，在前者任职的13年职业生涯中他担任过全球性和全国性领导职位。Francis先生最后担任该公司的美国商业组织的高级副总裁。从1998年到2001年，Francis先生在英国赛诺菲集团（Sanofi）任职，他在该公司的泌尿、镇痛和心血管产品部门担任过多个营销职位。他还担任过Lorex Synthelabo和惠氏公司（Wyeth）担任过销售与市场部的多个职位。Francis先生在英国曼彻斯特城市大学（Manchester Metropolitan University）获得经济学文学学士学位。
Richard Francis,has been a director since May 2016. He serves on the Compensation Committee. He has a Bachelor of Arts in Economics from the Manchester Metropolitan University. He is Chief Executive Officer and a Director of Teva Pharmaceutical Industries Ltd., since January 2023. He is a Director of Purespring Therapeutics, a kidney focused AAV gene therapy company, since January 2023.From February 2021 until December 2022, Mr. Francis was Chief Executive Officer of Purespring Therapeutics. From 2014 until March 2019, Mr. Francis was Division Head and Chief Executive Officer of Sandoz, the Generics Division of Novartis, and was a member of the Executive Committee of Novartis. Prior to that, Mr. Francis spent 13 years at Biogen Idec, where he held various global and country leadership positions. Immediately prior to leaving Biogen in 2014, Mr. Francis was Senior Vice President of their US commercial organization. From 1998 to 2001, he held various marketing roles at Sanofi. - Richard Francis从2014年5月1日开始一直担任山德士公司（Sandoz）的部门领导。他是诺华制药（Novartis）执行委员会委员。Francis先生从百健艾迪（Biogen Idec）离职加入诺华制药，在前者任职的13年职业生涯中他担任过全球性和全国性领导职位。Francis先生最后担任该公司的美国商业组织的高级副总裁。从1998年到2001年，Francis先生在英国赛诺菲集团（Sanofi）任职，他在该公司的泌尿、镇痛和心血管产品部门担任过多个营销职位。他还担任过Lorex Synthelabo和惠氏公司（Wyeth）担任过销售与市场部的多个职位。Francis先生在英国曼彻斯特城市大学（Manchester Metropolitan University）获得经济学文学学士学位。
- Richard Francis,has been a director since May 2016. He serves on the Compensation Committee. He has a Bachelor of Arts in Economics from the Manchester Metropolitan University. He is Chief Executive Officer and a Director of Teva Pharmaceutical Industries Ltd., since January 2023. He is a Director of Purespring Therapeutics, a kidney focused AAV gene therapy company, since January 2023.From February 2021 until December 2022, Mr. Francis was Chief Executive Officer of Purespring Therapeutics. From 2014 until March 2019, Mr. Francis was Division Head and Chief Executive Officer of Sandoz, the Generics Division of Novartis, and was a member of the Executive Committee of Novartis. Prior to that, Mr. Francis spent 13 years at Biogen Idec, where he held various global and country leadership positions. Immediately prior to leaving Biogen in 2014, Mr. Francis was Senior Vice President of their US commercial organization. From 1998 to 2001, he held various marketing roles at Sanofi.
- Elisha W. Finney
-
Elisha W. Finney自2016年1月起担任董事，任职于提名/公司治理委员会和审计委员会。 Finney女士于1999年4月被任命为 Varian Medical Systems的财务副总裁和首席财务官。2005年1月，她晋升为高级副总裁，并负责公司信息系统部门提供额外的管理。她于2012年2月被任命为执行副总裁。今天，Finney女士管理着全球400名员工。她的管理包括公司会计，公司通讯和投资者关系；内部财务和合规审计；风险管理；税务和财政，以及企业信息系统。 Finney女士于1988年加入Varian担任风险经理，在过去27年与公司合作，担任过各种财务职务。加入Varian之前，Finney女士在加州福斯特城的Fox Group和伊利诺伊州芝加哥的Beatrice Foods任职。 2005年8月至2005年7月当Laserscope被出售给 American Medical Systems时，Finney女士任职加利福尼亚州圣荷西Laserscope董事会。她于2007年7月至2013年5月在位于加利福尼亚州Pleasanton的Thoratec董事会任职。2011年9月至2015年12月Altera出售给Intel时，Finney在加利福尼亚州圣荷西Altera Corporation董事会任职。
Elisha W. Finney,has been a director since November 2017. She serves as Chair of the Audit Committee. She has a Bachelor's of Business Administration in Risk Management and Insurance from the University of Georgia, and a Master's in Business Administration from Golden Gate University.Ms. Finney is a Director and the Chair of the Audit Committee of NanoString Technologies, Inc., and a Director at ICU Medical, Inc. and Viatris Inc, where she is a member of the Audit Committee for both companies. She previously was a Director of Cutera, Inc. until June 2019 and iRobot Corporation until November 2021.Ms. Finney was the Chief Financial Officer of Varian Medical Systems Inc. from 1999 until her retirement in June 2017. She joined Varian in 1988 and served in a variety of finance roles prior to her appointment as CFO. - Elisha W. Finney自2016年1月起担任董事，任职于提名/公司治理委员会和审计委员会。 Finney女士于1999年4月被任命为 Varian Medical Systems的财务副总裁和首席财务官。2005年1月，她晋升为高级副总裁，并负责公司信息系统部门提供额外的管理。她于2012年2月被任命为执行副总裁。今天，Finney女士管理着全球400名员工。她的管理包括公司会计，公司通讯和投资者关系；内部财务和合规审计；风险管理；税务和财政，以及企业信息系统。 Finney女士于1988年加入Varian担任风险经理，在过去27年与公司合作，担任过各种财务职务。加入Varian之前，Finney女士在加州福斯特城的Fox Group和伊利诺伊州芝加哥的Beatrice Foods任职。 2005年8月至2005年7月当Laserscope被出售给 American Medical Systems时，Finney女士任职加利福尼亚州圣荷西Laserscope董事会。她于2007年7月至2013年5月在位于加利福尼亚州Pleasanton的Thoratec董事会任职。2011年9月至2015年12月Altera出售给Intel时，Finney在加利福尼亚州圣荷西Altera Corporation董事会任职。
- Elisha W. Finney,has been a director since November 2017. She serves as Chair of the Audit Committee. She has a Bachelor's of Business Administration in Risk Management and Insurance from the University of Georgia, and a Master's in Business Administration from Golden Gate University.Ms. Finney is a Director and the Chair of the Audit Committee of NanoString Technologies, Inc., and a Director at ICU Medical, Inc. and Viatris Inc, where she is a member of the Audit Committee for both companies. She previously was a Director of Cutera, Inc. until June 2019 and iRobot Corporation until November 2021.Ms. Finney was the Chief Financial Officer of Varian Medical Systems Inc. from 1999 until her retirement in June 2017. She joined Varian in 1988 and served in a variety of finance roles prior to her appointment as CFO.
- Domitille Doat Le Bigot
-
Domitille Doat Le Bigot从2020年2月开始担任董事。她拥有ESSEC商学院和墨尔本商学院的工商管理硕士学位。 自2016年以来，她一直担任达能的首席数字官，并且是嘉士伯集团董事会成员。
Domitille Doat Le Bigot,has been a director since February 2020. She serves on the Nominating & Corporate Governance Committee. She has a Master's in Business Administration from the ESSEC Business School and the Melbourne Business School. She has been Chief Digital Officer at Eurazeo, since April 2021. She is currently a member of the Board of Directors at Gaztransport & Technigaz (GTT), and of the Advisory Digital Board at Carlsberg Group and until 2020 was a member of its board.Prior to her current position, Ms. Doat-Le Bigot served as Chief Digital Officer at Danone from 2016 to 2021, and from 2014 to 2016 she served as Deputy General Manager and Head of Technology and Data in Shanghai and Paris at Fred & Farid Group, an international independent digital agency. Prior to 2014 she served in creative management and digital production and design positions at Cisco and Ubisoft Entertainment. - Domitille Doat Le Bigot从2020年2月开始担任董事。她拥有ESSEC商学院和墨尔本商学院的工商管理硕士学位。 自2016年以来，她一直担任达能的首席数字官，并且是嘉士伯集团董事会成员。
- Domitille Doat Le Bigot,has been a director since February 2020. She serves on the Nominating & Corporate Governance Committee. She has a Master's in Business Administration from the ESSEC Business School and the Melbourne Business School. She has been Chief Digital Officer at Eurazeo, since April 2021. She is currently a member of the Board of Directors at Gaztransport & Technigaz (GTT), and of the Advisory Digital Board at Carlsberg Group and until 2020 was a member of its board.Prior to her current position, Ms. Doat-Le Bigot served as Chief Digital Officer at Danone from 2016 to 2021, and from 2014 to 2016 she served as Deputy General Manager and Head of Technology and Data in Shanghai and Paris at Fred & Farid Group, an international independent digital agency. Prior to 2014 she served in creative management and digital production and design positions at Cisco and Ubisoft Entertainment.
- Wolfgang Wienand
-
Wolfgang Wienand,Wienand博士是Siegfried Holding AG （SIX： SFZN）的首席执行官，Siegfried Holding AG是制药行业合同开发和制造（CDMO）的全球领导者。他于2010年加入Siegfried，担任执行委员会成员，最初担任首席科学官，然后担任首席战略官，后来在2019年成为首席执行官之前同时担任这两个职位。加入Siegfried之前，他曾担任Evonik Industries AG（全球领先的特种化学品公司）的高级管理职位。
Wolfgang Wienand,has been a director since November 2023. He has been the Chief Executive Officer of Siegfried Holding AG, a global leader in contract development and manufacturing (CDMO) for the pharmaceutical industry, since January 2019. He studied chemistry at the University of Bonn and subsequently obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master's Degree in International Finance of cole des hautes études commerciales HEC Paris.Dr. Wienand joined Siegfried in 2010 as Member of the Executive Committee, initially serving as Chief Scientific Officer, then as Chief Strategy Officer, and later holding both positions in parallel before becoming CEO. Prior to Siegfried, Dr. Wienand held senior management positions at Evonik Industries AG, a leading global specialty chemicals company. Dr. Wienand serves as a non-executive board member for SCHOTT Pharma. - Wolfgang Wienand,Wienand博士是Siegfried Holding AG （SIX： SFZN）的首席执行官，Siegfried Holding AG是制药行业合同开发和制造（CDMO）的全球领导者。他于2010年加入Siegfried，担任执行委员会成员，最初担任首席科学官，然后担任首席战略官，后来在2019年成为首席执行官之前同时担任这两个职位。加入Siegfried之前，他曾担任Evonik Industries AG（全球领先的特种化学品公司）的高级管理职位。
- Wolfgang Wienand,has been a director since November 2023. He has been the Chief Executive Officer of Siegfried Holding AG, a global leader in contract development and manufacturing (CDMO) for the pharmaceutical industry, since January 2019. He studied chemistry at the University of Bonn and subsequently obtained a Ph.D. in organic and bioorganic chemistry from the University of Cologne. In addition, he holds an Executive Master's Degree in International Finance of cole des hautes études commerciales HEC Paris.Dr. Wienand joined Siegfried in 2010 as Member of the Executive Committee, initially serving as Chief Scientific Officer, then as Chief Strategy Officer, and later holding both positions in parallel before becoming CEO. Prior to Siegfried, Dr. Wienand held senior management positions at Evonik Industries AG, a leading global specialty chemicals company. Dr. Wienand serves as a non-executive board member for SCHOTT Pharma.
- Michael A. Kelly
-
Michael A. Kelly， 自2008年7月起出任董事，并担任薪酬委员会委员。自2012年10月他担任3M公司电子和能源业务执行副总裁，之前自2006年10月他曾任该公司显示与图形执行副总裁。在此之前，自从他在1981年加入了3M，他曾在美国，新加坡韩国和德国担任多个管理职位。他曾在宾夕法尼亚大学沃顿商学院读完了行政教育。在他担任3M公司的电子和能源业务的执行副总裁期间，他要负责这价值60亿的全球业务所有运营和策略工作，包括3M的电子材料，电气市场，通信市场，电子解决方案，可再生能源，以及光学系统业务。
Michael A. Kelly,has been a director since July 2008. He serves on the Audit and Compensation Committees. He has completed executive education at The Wharton School of the University of Pennsylvania. He is a Director of HERC Holdings Inc., where he is Chair of the Compensation Committee.Mr. Kelly spent many years as an executive at 3M Company, serving as Executive Vice President of the Electronics and Energy Business from October 2012 to January 2016, and Executive Vice President of the Display and Graphics Business from October 2006 to October 2012. He served in various management positions in the U.S., Singapore, Korea, and Germany since he joined 3M in 1981.In his role as the Executive Vice President of 3M's Electronics and Energy Business, Mr. Kelly had global responsibility for all operational and strategic elements of a $6 billion business, including the Electronic Materials, Electrical Markets, Communications Markets, Renewable Energy, and Display Materials Systems Businesses of 3M. Mr. Kelly's business also encompassed all film manufacturing for 3M. As a result of running this complex and highly technical set of global businesses, Mr. Kelly has experience in several topics relevant to the company, including strategic planning, restructuring, shifting business focus to emerging markets, and operational matters generally. - Michael A. Kelly， 自2008年7月起出任董事，并担任薪酬委员会委员。自2012年10月他担任3M公司电子和能源业务执行副总裁，之前自2006年10月他曾任该公司显示与图形执行副总裁。在此之前，自从他在1981年加入了3M，他曾在美国，新加坡韩国和德国担任多个管理职位。他曾在宾夕法尼亚大学沃顿商学院读完了行政教育。在他担任3M公司的电子和能源业务的执行副总裁期间，他要负责这价值60亿的全球业务所有运营和策略工作，包括3M的电子材料，电气市场，通信市场，电子解决方案，可再生能源，以及光学系统业务。
- Michael A. Kelly,has been a director since July 2008. He serves on the Audit and Compensation Committees. He has completed executive education at The Wharton School of the University of Pennsylvania. He is a Director of HERC Holdings Inc., where he is Chair of the Compensation Committee.Mr. Kelly spent many years as an executive at 3M Company, serving as Executive Vice President of the Electronics and Energy Business from October 2012 to January 2016, and Executive Vice President of the Display and Graphics Business from October 2006 to October 2012. He served in various management positions in the U.S., Singapore, Korea, and Germany since he joined 3M in 1981.In his role as the Executive Vice President of 3M's Electronics and Energy Business, Mr. Kelly had global responsibility for all operational and strategic elements of a $6 billion business, including the Electronic Materials, Electrical Markets, Communications Markets, Renewable Energy, and Display Materials Systems Businesses of 3M. Mr. Kelly's business also encompassed all film manufacturing for 3M. As a result of running this complex and highly technical set of global businesses, Mr. Kelly has experience in several topics relevant to the company, including strategic planning, restructuring, shifting business focus to emerging markets, and operational matters generally.
- Thomas P. Salice
-
Thomas P. Salice，2005年1月至今为私募股权公司 SFW Capital Partners, LLC 的联合创始人兼管理成员。曾在私募股权公司 AEA Investors, Inc. 担任各种职务，包括董事总经理、总裁兼首席执行官和副主席（1989年6月至2004年12月）。几家私营公司的董事：Filtec and Gerson Lehrman Group, Inc. 和 Micromeritics Instrument Corporation。
Thomas P. Salice,has been a director since October 1996. He serves as Chair of the Compensation and Nominating & Corporate Governance Committees. He has a Master's in Business Administration from Harvard University. Mr. Salice is a co-founder, principal, and Managing Member of SFW Capital Partners, LLC. Mr. Salice was a Director of Waters Corporation until July 2022, and he is currently a Director of the privately-held companies Caron Products and Services Inc., Gerson Lehrman Group, Inc., Micromeritics Instrument Corporation, and Pion Inc.Mr. Salice has been a Managing Member of SFW Capital Partners since January 2005. From June 1989 to December 2004, he served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer, and Vice-Chair. - Thomas P. Salice，2005年1月至今为私募股权公司 SFW Capital Partners, LLC 的联合创始人兼管理成员。曾在私募股权公司 AEA Investors, Inc. 担任各种职务，包括董事总经理、总裁兼首席执行官和副主席（1989年6月至2004年12月）。几家私营公司的董事：Filtec and Gerson Lehrman Group, Inc. 和 Micromeritics Instrument Corporation。
- Thomas P. Salice,has been a director since October 1996. He serves as Chair of the Compensation and Nominating & Corporate Governance Committees. He has a Master's in Business Administration from Harvard University. Mr. Salice is a co-founder, principal, and Managing Member of SFW Capital Partners, LLC. Mr. Salice was a Director of Waters Corporation until July 2022, and he is currently a Director of the privately-held companies Caron Products and Services Inc., Gerson Lehrman Group, Inc., Micromeritics Instrument Corporation, and Pion Inc.Mr. Salice has been a Managing Member of SFW Capital Partners since January 2005. From June 1989 to December 2004, he served in a variety of capacities with AEA Investors, Inc., including Managing Director, President and Chief Executive Officer, and Vice-Chair.
- Ingrid Zhang
-
Ingrid Zhang，自2023年2月起担任董事。她目前是Novartis创新药物中国区总裁。在担任这一职务之前，她曾在2017年至2022年期间担任Novartis制药中国区总裁，自2011年以来，她还在Novartis担任过多个领导职务，职责越来越多。在加入Novartis之前，Zhang女士曾在AstraZeneca、Pfizer和McKinsey & Company担任过多个高级管理职位。
Ingrid Zhang,has been a director since February 2023. She is currently the President and Managing Director of Novartis China. Prior to this role, she was President of China, Innovative Medicines at Novartis, from 2022 to October 2023, President Novartis Pharmaceuticals China from 2017 to 2022, and held several other leadership positions with increasing responsibilities at Novartis since 2011. Prior to Novartis, Ms. Zhang held various senior management roles with AstraZeneca, Pfizer, and McKinsey & Company. - Ingrid Zhang，自2023年2月起担任董事。她目前是Novartis创新药物中国区总裁。在担任这一职务之前，她曾在2017年至2022年期间担任Novartis制药中国区总裁，自2011年以来，她还在Novartis担任过多个领导职务，职责越来越多。在加入Novartis之前，Zhang女士曾在AstraZeneca、Pfizer和McKinsey & Company担任过多个高级管理职位。
- Ingrid Zhang,has been a director since February 2023. She is currently the President and Managing Director of Novartis China. Prior to this role, she was President of China, Innovative Medicines at Novartis, from 2022 to October 2023, President Novartis Pharmaceuticals China from 2017 to 2022, and held several other leadership positions with increasing responsibilities at Novartis since 2011. Prior to Novartis, Ms. Zhang held various senior management roles with AstraZeneca, Pfizer, and McKinsey & Company.
高管简历
中英对照 | 中文 | 英文- Patrick Kaltenbach
Patrick Kaltenbach于2021年1月加入Mettler-Toledo International Inc.，担任候任首席执行官，自2021年4月1日起担任首席执行官。在加入公司之前，他自2018年起担任Becton Dickinson生命科学部门的总裁。2014年至2018年，他担任安捷伦生命科学和应用市场集团总裁。此前，自1991年加入安捷伦及其前身惠普（Hewlett-Packard）以来，他在安捷伦（Agilent）担任了范围广泛且越来越多的领导职务。
Patrick Kaltenbach,joined the Company in January 2021 and assumed the role of Chief Executive Officer beginning April 1, 2021. Prior to joining the Company, he served as the President of the Life Sciences Segment at Becton Dickinson since 2018. He was President of Life Sciences and Applied Markets Group at Agilent from 2014 to 2018. Previously, he held wide-ranging and increasing leadership roles at Agilent and its predecessor company, Hewlett Packard, since joining in 1991.- Patrick Kaltenbach于2021年1月加入Mettler-Toledo International Inc.，担任候任首席执行官，自2021年4月1日起担任首席执行官。在加入公司之前，他自2018年起担任Becton Dickinson生命科学部门的总裁。2014年至2018年，他担任安捷伦生命科学和应用市场集团总裁。此前，自1991年加入安捷伦及其前身惠普（Hewlett-Packard）以来，他在安捷伦（Agilent）担任了范围广泛且越来越多的领导职务。
- Patrick Kaltenbach,joined the Company in January 2021 and assumed the role of Chief Executive Officer beginning April 1, 2021. Prior to joining the Company, he served as the President of the Life Sciences Segment at Becton Dickinson since 2018. He was President of Life Sciences and Applied Markets Group at Agilent from 2014 to 2018. Previously, he held wide-ranging and increasing leadership roles at Agilent and its predecessor company, Hewlett Packard, since joining in 1991.
- Shawn P. Vadala
Shawn P. Vadala，他于1997年加入公司，并一直担任首席财务官（2004年1月以来）。他负责公司的定价和商业智能项目。他此前曾担任公司的俄亥俄州哥伦布、瑞士格里芬湖办公室的多种高级财务职务。加入公司之前，他曾任职PricewaterhouseCoopers公司的波士顿和瑞士、苏黎世办事处。
Shawn P. Vadala,joined the Company in 1997 and has been Chief Financial Officer since January 2014 and also responsible for the Company's Pricing program since 2008. Mr. Vadala previously held various senior financial positions at the Company's Columbus, Ohio and Greifensee, Switzerland offices and was also responsible for Business Intelligence from 2010 to 2018. Prior to joining the Company, he worked in the Boston and Zurich, Switzerland offices of PricewaterhouseCoopers.- Shawn P. Vadala，他于1997年加入公司，并一直担任首席财务官（2004年1月以来）。他负责公司的定价和商业智能项目。他此前曾担任公司的俄亥俄州哥伦布、瑞士格里芬湖办公室的多种高级财务职务。加入公司之前，他曾任职PricewaterhouseCoopers公司的波士顿和瑞士、苏黎世办事处。
- Shawn P. Vadala,joined the Company in 1997 and has been Chief Financial Officer since January 2014 and also responsible for the Company's Pricing program since 2008. Mr. Vadala previously held various senior financial positions at the Company's Columbus, Ohio and Greifensee, Switzerland offices and was also responsible for Business Intelligence from 2010 to 2018. Prior to joining the Company, he worked in the Boston and Zurich, Switzerland offices of PricewaterhouseCoopers.
- Peter Aggersbjerg
Peter Aggersbjerg自2018年1月起担任公司实验室主任。2016年2月至2017年12月，他担任实验室称重战略业务部门负责人。 他于2011年2月起担任Medela新生儿护理业务全球业务负责人及集团管理层成员，直至2016年2月加入公司。在Medela之前，Aggersbjerg先生于2010年7月至2011年2月担任Swissimplant首席执行官。 2006年至2008年12月和Tytex于2001年10月至2006年10月。
Peter Aggersbjerg,has been Head of Divisions since January 2020 and Head of Laboratory since January 2018. From February 2016 to December 2017, he served as the Head of Mettler-Toledo International Inc. Laboratory Weighing strategic business unit. Prior to joining the Company, he served as the Global BU Head for Medela's Neonatal Care business and a member of its Group management. Prior to Medela, Mr. Aggersbjerg worked in various CEO roles in the health care, medical devices, and industrial sectors in Switzerland, Denmark, and the U.S. Mr. Aggersbjerg will depart the Company at the end of February 2023 at which time Stefan Heiniger will become the Head of Laboratory. Mr. Heiniger has been the Head of Laboratory Weighing since 2018.- Peter Aggersbjerg自2018年1月起担任公司实验室主任。2016年2月至2017年12月，他担任实验室称重战略业务部门负责人。 他于2011年2月起担任Medela新生儿护理业务全球业务负责人及集团管理层成员，直至2016年2月加入公司。在Medela之前，Aggersbjerg先生于2010年7月至2011年2月担任Swissimplant首席执行官。 2006年至2008年12月和Tytex于2001年10月至2006年10月。
- Peter Aggersbjerg,has been Head of Divisions since January 2020 and Head of Laboratory since January 2018. From February 2016 to December 2017, he served as the Head of Mettler-Toledo International Inc. Laboratory Weighing strategic business unit. Prior to joining the Company, he served as the Global BU Head for Medela's Neonatal Care business and a member of its Group management. Prior to Medela, Mr. Aggersbjerg worked in various CEO roles in the health care, medical devices, and industrial sectors in Switzerland, Denmark, and the U.S. Mr. Aggersbjerg will depart the Company at the end of February 2023 at which time Stefan Heiniger will become the Head of Laboratory. Mr. Heiniger has been the Head of Laboratory Weighing since 2018.
- Gerhard Keller
Gerhard Keller，1991年加入公司，自2018年7月起担任过程分析主管，自2013年7月起担任移液器主管。他此前担任东亚/太平洋区域主管，还曾在欧洲和亚太地区担任多个销售和营销领导职能。在加入公司之前，他曾在瑞士的Sandoz（现为诺华）从事质量控制工作。
Gerhard Keller,joined the Company in 1991 and has been Head of Process Analytics since July 2018 and Head of Pipettes since July 2013. He previously was Head of Region East Asia/Pacific and also served in various Sales and Marketing leadership functions in Europe and Asia Pacific. Prior to joining the Company, he worked in Quality Control at Sandoz, now Novartis, in Switzerland.- Gerhard Keller，1991年加入公司，自2018年7月起担任过程分析主管，自2013年7月起担任移液器主管。他此前担任东亚/太平洋区域主管，还曾在欧洲和亚太地区担任多个销售和营销领导职能。在加入公司之前，他曾在瑞士的Sandoz（现为诺华）从事质量控制工作。
- Gerhard Keller,joined the Company in 1991 and has been Head of Process Analytics since July 2018 and Head of Pipettes since July 2013. He previously was Head of Region East Asia/Pacific and also served in various Sales and Marketing leadership functions in Europe and Asia Pacific. Prior to joining the Company, he worked in Quality Control at Sandoz, now Novartis, in Switzerland.
- Richard Wong
Richard Wong自2009年起担任亚太市场组织负责人。在2008年加入公司之前，他曾于1998年至2008年在安捷伦科技公司担任过多个区域管理职位，包括总部位于北京和东京的北亚生命科学现场运营。1991年，他在惠普公司开始了他的职业生涯，并在销售与市场营销和财务部门担任了越来越多的职务。
Richard Wong,has been Head of Asia/Pacific since 2009. Prior to joining the Company in 2008, he held various regional management positions with Agilent Technologies from 1998 to 2008 including Life Sciences Field Operations for North Asia based in Beijing and later in Tokyo. He started his career with Hewlett Packard in 1991 and held positions of increasing responsibilities in Sales and Marketing and Finance.- Richard Wong自2009年起担任亚太市场组织负责人。在2008年加入公司之前，他曾于1998年至2008年在安捷伦科技公司担任过多个区域管理职位，包括总部位于北京和东京的北亚生命科学现场运营。1991年，他在惠普公司开始了他的职业生涯，并在销售与市场营销和财务部门担任了越来越多的职务。
- Richard Wong,has been Head of Asia/Pacific since 2009. Prior to joining the Company in 2008, he held various regional management positions with Agilent Technologies from 1998 to 2008 including Life Sciences Field Operations for North Asia based in Beijing and later in Tokyo. He started his career with Hewlett Packard in 1991 and held positions of increasing responsibilities in Sales and Marketing and Finance.
- Marc de la Gueronniere
Marc de la Gueronniere，自2008年1月以来一直是该公司European Market Organizations主管。2006年1月-2008年1月期间，曾是西班牙南部地区的主管，以及是该公司（Spain）市场组织总经理。他于2001年加入该公司并在法国（France）本市场组织担任工业业务领域经理。在加入该公司之前，曾在欧洲（Europe）、美国（United States）的ABB-Elsag Bailey以及Danaher-Zellweger担任各种管理职位。
Marc de la Gueronniere,has been Head of European Market Organizations of the Company since January 2008 and Head of North American Market Organizations since April 2014. He was Head of Region South and General Manager of the Company's market organization in Spain from January 2006 to January 2008. He joined the Company in 2001 as the Industrial Business Area Manager for Mettler-Toledo International Inc. market organization in France. Prior to joining the Company, Mr. de La Guéronnière held various management positions in Europe and the United States with ABB-Elsag Bailey and Danaher-Zellweger.- Marc de la Gueronniere，自2008年1月以来一直是该公司European Market Organizations主管。2006年1月-2008年1月期间，曾是西班牙南部地区的主管，以及是该公司（Spain）市场组织总经理。他于2001年加入该公司并在法国（France）本市场组织担任工业业务领域经理。在加入该公司之前，曾在欧洲（Europe）、美国（United States）的ABB-Elsag Bailey以及Danaher-Zellweger担任各种管理职位。
- Marc de la Gueronniere,has been Head of European Market Organizations of the Company since January 2008 and Head of North American Market Organizations since April 2014. He was Head of Region South and General Manager of the Company's market organization in Spain from January 2006 to January 2008. He joined the Company in 2001 as the Industrial Business Area Manager for Mettler-Toledo International Inc. market organization in France. Prior to joining the Company, Mr. de La Guéronnière held various management positions in Europe and the United States with ABB-Elsag Bailey and Danaher-Zellweger.
- Christian Magloth
Christian Magloth，于2010年10月加入该公司；自2010年12月以来，一直是人力资源主管。在加入该公司之前，他曾于2006年4月-2010年9月期间，在一家瑞士证券交易所（Swiss stock exchange）上市的大型全球医疗设备公司- Straumann，担任人力资源总监。他此前曾在一家国际消费食品公司- Hero Group担任人力资源总监，以及在一家大型全球建筑供应公司- Hilti担任各种管理职位。
Christian Magloth,joined the Company in October 2010 and has been Head of Human Resources since December 2010. Prior to joining the Company, he served as Head of Human Resources of Straumann, a leading global medical devices company listed on the Swiss stock exchange, from April 2006 to September 2010. He previously served as Head of Human Resources at Hero Group, an international consumer foods company, and in various management positions at Hilti, a leading global construction supply company.- Christian Magloth，于2010年10月加入该公司；自2010年12月以来，一直是人力资源主管。在加入该公司之前，他曾于2006年4月-2010年9月期间，在一家瑞士证券交易所（Swiss stock exchange）上市的大型全球医疗设备公司- Straumann，担任人力资源总监。他此前曾在一家国际消费食品公司- Hero Group担任人力资源总监，以及在一家大型全球建筑供应公司- Hilti担任各种管理职位。
- Christian Magloth,joined the Company in October 2010 and has been Head of Human Resources since December 2010. Prior to joining the Company, he served as Head of Human Resources of Straumann, a leading global medical devices company listed on the Swiss stock exchange, from April 2006 to September 2010. He previously served as Head of Human Resources at Hero Group, an international consumer foods company, and in various management positions at Hilti, a leading global construction supply company.